| Ytd | -55.22% | |
| 1y | 188.61% |
| Open | 2.99 | Prev Close | 2.99 | Low | 2.93 | High | 3.15 | Mkt Cap | 202.67M |
| Vol | 622.21K | Avg Vol | 933.96K | EPS | -1.31 | P/E | -2.24 | Forward P/E | -1.45 |
| Beta | 1.89 | Short Ratio | 5.75 | Inst. Own | 96.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 1.88 | 200-d Avg | 3.81 | 1yr Est | 15.40 |
PEPG News
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next g
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of
Independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FR
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Rec
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Pha
Craig-Hallum analyst Adam Vogel initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of o
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancin
PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exh
https://www.sec.gov/Archives/edgar/data/1835597/000119312526228960/d132482ds3.htm
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected
Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancin
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen I
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Top Wall Street analysts changed their outlook on top names. For a complete view of all rating chang
Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims
Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price
US stocks higher, Dow up 0.90%, Nasdaq up 1.61%. Communication services gained 1.8%, utilities fell
PepGen stock drops after Phase 2 low-dose data show limited splicing correction; higher-dose cohorts
Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its s
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of o
Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 r
U.S. stock futures mixed, Grocery Outlet Holding Corp shares fall 26.3% in pre-market trading after
Shares of Veeva Systems Inc (NYSE: VEEV) gained 11.3% in pre-market trading on upbeat Q4 results and
PepGen (PEPG) shifts focus to DM1 but faces a fresh FDA roadblock. Clinical data, analyst ratings, a
- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and to
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.27) per share which beat the analyst consensus
Oppenheimer analyst Kostas Biliouris initiates coverage on PepGen (NASDAQ:PEPG) with a Outperform
Guggenheim analyst Debjit Chattopadhyay maintains PepGen (NASDAQ:PEPG) with a Buy and raises the
